BioCryst Pharma (BCRX) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.77 +0.11%
EPS Growth %: -43.8%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -43.8%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.32), $0.02 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $63.33 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- KT&G approves KRW 360 billion share buyback and retirement plan
- Exelon (EXC) PT Lowered to $49 at Argus
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
